Investigational drug · Phase 2
RTN-001
Also called: SLx-2101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Uncontrolled Hypertension.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "RTN-001"
First trial start
2025
Oct 31, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RTN-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Uncontrolled Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "RTN-001" as an intervention, largest first.
- A Study of Modified Release RTN-001 In Patients With Uncontrolled HypertensionPivotal-lookingRecruiting
Retension Pharmaceuticals. Inc.Industry
NCT07142356 · 280 participants (planned) · Start Oct 31, 2025 · Primary completion Mar 2027
Drug: RTN-001; Matching placebo control · For: Uncontrolled Hypertension
Sites: Alexander City, Alabama; Birmingham, Alabama; Glendale, Arizona · 44 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- AI-assisted identification of a novel vardenafil analog (KD-027) adulterated in capsules.
Yen YT, Wang YT, Lin TC, et al. · J Forensic Sci 2026
- Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments.
Melchiode Z, Nguyen T, Dawood O, et al. · Expert Opin Investig Drugs 2023
- New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?
Paulis L, Rajkovicova R, Simko F · Curr Hypertens Rep 2015
- Emerging drugs for the treatment of erectile dysfunction.
Peak TC, Yafi FA, Sangkum P, et al. · Expert Opin Emerg Drugs 2015
- Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.
Kedia GT, Uckert S, Assadi-Pour F, et al. · Ther Adv Urol 2013
- The management of erectile dysfunction: innovations and future perspectives.
Leonardi R, Alemanni M · Arch Ital Urol Androl 2011
Also in development for Uncontrolled Hypertension
- SAL0120Phase 32 trials
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Chronic Kidney Disease, Uncontrolled Hypertension, Resistant Hypertension
- SAL0140Phase 23 trials
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Primary Aldosteronism, Chronic Kidney Disease, Uncontrolled Hypertension
- of QLS1410Phase 22 trials
Qilu Pharmaceutical Co., Ltd. · Hypertension (HTN), Uncontrolled Hypertension
- SYH2072Phase 22 trials
InnovStone Therapeutics Limited · Uncontrolled Hypertension, Resistant Hypertension, Primary Aldosteronism
- VB19055Phase 21 trial
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. · Hypertension, Resistant Hypertension, Uncontrolled Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.